Bloxiverz Disease Interactions
There are 9 disease interactions with Bloxiverz (neostigmine).
- Bradycardia
- Bronchospasm
- Coronary artery disease
- Parkinsonism
- PUD
- Seizures
- Intestinal/urinary obstruction
- Hyperthyroidism
- Hepatic impairment
Cholinesterase inhibitor (applies to Bloxiverz) bradycardia
Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias
Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block. Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities. Syncopal episodes have been reported in patients with and without cardiac abnormalities. Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.
Cholinesterase inhibitor (applies to Bloxiverz) bronchospasm
Major Potential Hazard, High plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease, Asthma
Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine. The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm. Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease. Monitoring respiratory function during dosage initiation and adjustment is recommended. Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress. Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium. However, the duration of action is longest for ambenonium and shortest for edrophonium. Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.
Cholinesterase inhibitor (applies to Bloxiverz) coronary artery disease
Major Potential Hazard, High plausibility. Applicable conditions: Ischemic Heart Disease
The use of cholinesterase inhibitors has been associated with a constriction of coronary arteries. Therapy with cholinesterase inhibitors should be administered cautiously in patients with coronary artery disease.
Cholinesterase inhibitor (applies to Bloxiverz) parkinsonism
Major Potential Hazard, High plausibility.
Cholinesterase inhibitors should be used with caution in patients with parkinsonism. Some of these drugs might be contraindicated in these patients (refer to specific prescribing information). Symptoms of Parkinson's disease may be exacerbated with the increase in cholinergic activity. Caregivers and patients should be advised.
Cholinesterase inhibitor (applies to Bloxiverz) PUD
Major Potential Hazard, High plausibility. Applicable conditions: Peptic Ulcer
The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions. Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.
Cholinesterase inhibitor (applies to Bloxiverz) seizures
Major Potential Hazard, High plausibility.
Cholinesterase inhibitors have been associated with convulsions and tremor. Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.
Neostigmine (applies to Bloxiverz) intestinal/urinary obstruction
Major Potential Hazard, Moderate plausibility. Applicable conditions: Intestinal Obstruction, Urinary Tract Obstruction
Neostigmine is contraindicated in mechanical obstruction of the urinary or intestinal tract and peritonitis.
Cholinesterase inhibitor (applies to Bloxiverz) hyperthyroidism
Moderate Potential Hazard, High plausibility.
Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors. Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism. Monitoring of thyroid levels is recommended.
Neostigmine (applies to Bloxiverz) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Neostigmine is metabolized by microsomal enzymes in the liver, and the effect of hepatic impairment on pharmacokinetics has not been evaluated. Patients should be carefully monitored if hepatically cleared neuromuscular blocking agents are used, as their duration of action may be prolonged due to hepatic insufficiency.
Bloxiverz drug interactions
There are 109 drug interactions with Bloxiverz (neostigmine).
More about Bloxiverz (neostigmine)
- Bloxiverz consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: cholinergic muscle stimulants
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.